Anti–Interleukin-12 Antibody for Active Crohn's Disease

2004851 citationsJournal Articlebronze Open Access

Authors

Peter Mannon · National Institute of Allergy and Infectious Diseases

Ivan J. Fuss · National Institute of Allergy and Infectious Diseases

Lloyd Mayer · Icahn School of Medicine at Mount Sinai

Charles O. Elson · University of Alabama at Birmingham

William J. Sandborn · Mayo Clinic in Arizona

Daniel H. Present · Icahn School of Medicine at Mount Sinai

Ben J. Dolin

Abstract

Treatment with a monoclonal antibody against interleukin-12 may induce clinical responses and remissions in patients with active Crohn's disease. This treatment is associated with decreases in Th1-mediated inflammatory cytokines at the site of disease.

Topics & Keywords

Inflammatory Bowel Disease Microscopic Colitis Immunodeficiency and Autoimmune Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 351, Issue 20, pp. 2069-2079

DOI: 10.1056/nejmoa033402

Field-Weighted Citation Impact: 40.29